Last updated on March 2018

Patients are needed to participate in a clinical research study evaluating etrolizumab, infliximab for the treatment of Ulcerative Colitis

Brief description of study

This is a multicenter, Phase III, randomized, double-blind, double-dummy, parallel-group study to evaluate the safety, efficacy, and tolerability of etrolizumab compared with infliximab in treating participants with moderate to severe ulcerative colitis (UC) who are naive to tumor necrosis factor (TNF) inhibitors. Participants will be randomized in a 1:1 ratio to receive either etrolizumab 105 (milligrams) by subcutaneous (SC) injection [SC] every 4 weeks [Q4W]) + placebo (intravenous [IV] infusion at Weeks 0, 2, and 6, then every 8 weeks) or infliximab 5 milligrams/kilogram (mg/kg) IV at Weeks 0, 2, and 6, then every 8 weeks) + placebo (SC Q4W). Time on treatment is 54 weeks.

Clinical Study Identifier: NCT02136069

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: GA29103 ...

AZ Sint Elisabeth Herentals
Herentals, Belgium
  Connect »